Inactive Instrument

Analyst Reco. Prometheus Biosciences, Inc.

Equities

RXDX

US74349U1088

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

S&P 500 Posts Weekly Decline Led by Real Estate, Energy as Fed Officials Point to More Rate Increases	23/06/23	MT
Jefferies Downgrades Prometheus Biosciences to Hold From Buy, Adjusts Price Target to $200 From $160	10/05/23	MT
Credit Suisse Downgrades Prometheus Biosciences to Neutral From Outperform on Heels of Announced Sale to Merck & Co., Raises Price Target to $200 From $139	18/04/23	MT
RBC Downgrades Prometheus Biosciences to Sector Perform From Outperform, Lifts Price Target to $200 From $140 on Merck Deal; Speculative Risk Kept	18/04/23	MT
Wells Fargo Downgrades Prometheus Biosciences to Equalweight From Overweight, Adjusts Price Target to $200 From $164	18/04/23	MT
Piper Sandler Downgrades Prometheus Biosciences to Neutral From Overweight, Adjusts Price Target to $200 From $138	18/04/23	MT
Wall St slips as Fed seen hiking rates in May; State Street sinks	17/04/23	RE
Guggenheim Downgrades Prometheus Biosciences to Neutral From Buy, Cuts Price Target to $200 From $225	17/04/23	MT
Stifel Downgrades Prometheus Biosciences to Hold From Buy, Raises Price Target to $200 From $155	17/04/23	MT
Guggenheim Adjusts Price Target on Prometheus Biosciences to $225 From $185, Maintains Buy Rating	06/03/23	MT
Oppenheimer Adjusts Prometheus Biosciences Price Target to $150 From $125, Maintains Outperform Rating	01/03/23	MT
Credit Suisse Lowers Prometheus Biosciences' Price Target to $139 From $142, Keeps Outperform Rating	01/03/23	MT
Goldman Sachs Adjusts Price Target on Prometheus Biosciences to $144 From $117, Maintains Buy Rating	31/01/23	MT
Stifel Nicolaus Adjusts Prometheus Biosciences Price Target to $155 From $55, Maintains Buy Rating	12/12/22	MT
BTIG Adjusts Prometheus Biosciences' Price Target to $181 From $74, Keeps Buy Rating	08/12/22	MT
Oppenheimer Raises Prometheus Biosciences Price Target to $125 From $61, Maintains Outperform Rating	08/12/22	MT
Credit Suisse Raises Prometheus Biosciences' PT to $142 From $59, Updates Model to Reflect 'Strong' Phase 2 IBD Data; Keeps Outperform Rating	08/12/22	MT
RBC Boosts Price Target on Prometheus Biosciences to $111 From $66, Citing Strength of PRA023 Data, Keeps Outperform, Speculative Risk	08/12/22	MT
Stifel Raises Prometheus Biosciences' Price Target to $55 From $50, Keeps Buy Rating	01/11/22	MT
Oppenheimer Adjusts Prometheus Biosciences Price Target to $65 From $50, Maintains Outperform Rating	04/10/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Prometheus Biosciences, Inc.

Equities

RXDX

US74349U1088

Analyst Reco.

Filters